<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="EN" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Antimicrob Agents Chemother</journal-id><journal-id journal-id-type="pmc-domain-id">82</journal-id><journal-id journal-id-type="pmc-domain">aac</journal-id><journal-id journal-id-type="publisher-id">ANTIMICROB AGENTS CHEMOTHER</journal-id><journal-title-group><journal-title>Antimicrobial Agents and Chemotherapy</journal-title></journal-title-group><issn pub-type="ppub">0066-4804</issn><issn pub-type="epub">1098-6596</issn><publisher><publisher-name>American Society for Microbiology (ASM)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC89777</article-id><article-id pub-id-type="pmcid-ver">PMC89777.1</article-id><article-id pub-id-type="pmcaid">89777</article-id><article-id pub-id-type="pmcaiid">89777</article-id><article-id pub-id-type="pmid">10722476</article-id><article-id pub-id-type="doi">10.1128/aac.44.4.821-826.2000</article-id><article-id pub-id-type="publisher-id">0450</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Pharmacology</subject></subj-group></article-categories><title-group><article-title>Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor,  in Subjects with Normal or Impaired Hepatic Function</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Veronese</surname><given-names initials="L">Laurence</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">1</xref><xref ref-type="author-notes" rid="FN150">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rautaureau</surname><given-names initials="J">Jacques</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sadler</surname><given-names initials="BM">Brian M.</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gillotin</surname><given-names initials="C">Catherine</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petite</surname><given-names initials="JP">Jean-Pierre</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Pillegand</surname><given-names initials="B">Bernard</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Delvaux</surname><given-names initials="M">Michel</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Masliah</surname><given-names initials="C">Claude</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Fosse</surname><given-names initials="S">Sandrine</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lou</surname><given-names initials="Y">Yu</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stein</surname><given-names initials="DS">Daniel S.</given-names></name><xref ref-type="aff" rid="N0x964c898.0x9df65c0">3</xref></contrib></contrib-group><aff id="N0x964c898.0x9df65c0"> Laboratoire Glaxo Wellcome, 78163 Marly-le-Roi,<sup>1</sup> H&#244;pital Avicenne, 93000 Bobigny,<sup>2</sup> H&#244;pital Broussais, 75015 Paris,<sup>4</sup> H&#244;pital Dupuytren, 87042 Limoges,<sup>5</sup> H&#244;pital de Rangueil, 31400 Toulouse,<sup>6</sup> and  H&#244;tel-Dieu, 44035 Nantes,<sup>7</sup> France, and  Glaxo Wellcome, Inc., Research Triangle Park, North Carolina<sup>3</sup></aff><author-notes><fn id="FN150"><label>*</label><p>Corresponding author. Mailing address: Department of Clinical Pharmacology, Laboratoire Glaxo Wellcome, 78163 Marly-le-Roi, France. E-mail: <email>lv48262@glaxowellcome.co.uk</email>.</p></fn></author-notes><pub-date pub-type="ppub"><month>4</month><year>2000</year></pub-date><volume>44</volume><issue>4</issue><issue-id pub-id-type="pmc-issue-id">2483</issue-id><fpage>821</fpage><lpage>826</lpage><history><date date-type="received"><day>9</day><month>4</month><year>1999</year></date><date date-type="rev-request"><day>23</day><month>10</month><year>1999</year></date><date date-type="accepted"><day>27</day><month>12</month><year>1999</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>04</month><year>2000</year></date></event><event event-type="pmc-live"><date><day>12</day><month>09</month><year>2002</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2019-10-31 10:56:17.363"><day>31</day><month>10</month><year>2019</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2000, American Society for Microbiology</copyright-statement><copyright-year>2000</copyright-year></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ac000821.pdf"/><abstract><p>Amprenavir (141W94) is extensively metabolized by P450 cytochromes, specifically, CYP3A4. Because hepatic insufficiency reduces P450-mediated metabolism, the concentrations in plasma of drugs metabolized through this pathway are often increased in subjects with liver disease. Following administration of a single, oral dose of 600 mg of amprenavir, pharmacokinetic parameters were determined for 10 subjects with severe cirrhosis, 10 subjects with moderate cirrhosis, and 10 healthy volunteers. Model-independent methods for determining the area under the plasma concentration-time curve (AUC) from time zero to infinity (AUC<sub>0&#8211;&#8734;</sub>) showed an increase in amprenavir AUC<sub>0&#8211;&#8734;</sub> of 2.5-fold in the group with moderate cirrhosis and 4.5-fold in the group with severe cirrhosis compared with that in the control group of healthy volunteers (<italic>P</italic> &lt; 0.05). AUC<sub>0&#8211;&#8734;</sub> was linearly related to the severity of liver disease, as assessed by the Child-Pugh score. Of the laboratory data used to calculate the Child-Pugh score, only the mean total bilirubin concentration showed a significant relationship with AUC<sub>0&#8211;&#8734;</sub>. The relationship between the total bilirubin concentration and the AUC<sub>0&#8211;&#8734;</sub> of amprenavir was well characterized by a simple <italic>E</italic><sub>max</sub> model, suggesting that the total bilirubin concentration may be a useful parameter for predicting the amprenavir AUC in subjects with hepatic insufficiency. Finally, the sera of cirrhotic subjects showed significant decreases in the levels of &#945;<sub>1</sub>-acid glycoprotein, the primary plasma binding protein for amprenavir. On the basis of the results of this study, for an exposure equivalent to a clinical dose of 1,200 mg twice daily in subjects without cirrhosis, subjects with Child-Pugh scores of 5 to 8 should receive a twice-daily 450-mg dose of amprenavir, and subjects with Child-Pugh scores of 9 to 15 should receive a twice-daily 300-mg dose of amprenavir.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>